Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mesoblast Limited
  6. Summary
    MSB   AU000000MSB8

MESOBLAST LIMITED

(MSB)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
1.65 1.615 1.555 1.62 1.6 Last
1377042 1287122 2229676 2012132 2397576 Volume
-2.94% -2.12% -3.72% +4.18% -1.23% Change
Estimated financial data (e)
Sales 2022 46,4 M 33,0 M 33,0 M
Net income 2022 -131 M -93,3 M -93,3 M
Net cash position 2022 21,7 M 15,4 M 15,4 M
P/E ratio 2022 -6,08x
Yield 2022 -
Sales 2023 89,0 M 63,3 M 63,3 M
Net income 2023 -97,7 M -69,5 M -69,5 M
Net cash position 2023 23,1 M 16,4 M 16,4 M
P/E ratio 2023 -9,39x
Yield 2023 -
Capitalization 1 037 M 738 M 738 M
EV / Sales 2022 21,9x
EV / Sales 2023 11,4x
Nbr of Employees 83
Free-Float 85,7%
More Financials
Company
Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of... 
More about the company
Ratings of Mesoblast Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about MESOBLAST LIMITED
06:22aMESOBLAST : REXLEMESTROCEL-L SHOWS GREATEST TREATMENT BENEFIT ON MAJOR ADVERSE CARDIOVASCU..
PU
12/06Health Care Stocks Inch Higher Pre-Bell Monday
MT
12/06Health Care
MT
12/06Mesoblast's Heart Disease Drug Candidate Shows Most Benefit in Diabetes, Ischemia Patie..
MT
12/05Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Event..
GL
12/05MESOBLAST : Global CardioVascular Clinical Trialists Forum Presentation
PU
12/02MESOBLAST : CHAIRMAN'S ADDRESS TO SHAREHOLDERS 2021 MESOBLAST ANNUAL GENERAL MEETING - For..
PU
11/28MESOBLAST : CEO Presentation to 2021 Annual General Meeting
PU
11/26MESOBLAST : AND OAKTREE CAPITAL ENTER INTO REFINANCING AND EXPANSION OF SENIOR DEBT FACILI..
PU
11/24Mesoblast's Fiscal Q1 Loss Narrows, Revenue Grows
MT
11/23Mesoblast Narrows Net Loss in Fiscal Q1; Revenue Above Street Expectations
MT
11/23Operational Highlights and Financial Results for the Period Ended September 30, 2021
GL
11/23Operational Highlights and Financial Results for the Period Ended September 30, 2021
GL
11/23Mesoblast Limited Reports Earnings Results for the First Quarter Ended September 30, 20..
CI
11/23MESOBLAST : First Quarter Results Presentation
PU
More news
News in other languages on MESOBLAST LIMITED
12/06Les actions du secteur de la santé en hausse avant la cloche du lundi
12/06Soins de santé
12/06Le médicament candidat de Mesoblast pour les maladies cardiaques présente le plus d'ava..
11/24Mesoblast réduit sa perte au premier trimestre fiscal et augmente ses revenus
11/23Mesoblast réduit sa perte nette au premier trimestre de l'exercice ; le chiffre d'affai..
More news
Analyst Recommendations on MESOBLAST LIMITED
More recommendations
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast Limited Technical Analysis Chart | MSB | AU000000MSB8 | MarketScreener
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,60 AUD
Average target price 2,68 AUD
Spread / Average Target 67,2%
EPS Revisions
Managers and Directors
Silviu Itescu Chief Executive Officer, MD & Executive Director
Andrew Chaponnel Chief Financial Officer & Head-Finance
Joseph R. Swedish Independent Non-Executive Chairman
Fred Grossman Chief Medical Officer
Dagmar Rosa-Bjorkeson Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
MESOBLAST LIMITED-28.89%740
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-42.48%23 888